Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Related articles:
Related suggestion:
Senate passes reauthorization of key US surveillance programAfrica Energy Indaba highlights prospects of South AfricaUS says a UN agency has agreed to help in distribution of aid to Gaza via sea routeSean Penn displays his platinum white hair as he takes a smoke break during Malibu outingChina strives to refuel economy with green hydrogen energyVenezuela’s main opposition bloc agrees on candidate to challenge Maduro in presidential electionIsrael and Iran's apparent strikes give new insights into both militariesItaly approves participation in EU naval mission in Red SeaChina prepares to launch relay satellite QueqiaoChina's telecom sector logs steady growth in Jan
2.6763s , 6497.8984375 kb
Copyright © 2024 Powered by Lilly rides Mounjaro, Zepbound to better ,Global Gaze news portal